VRCA catalyst calendar

Verrica Pharmaceuticals Inc.

Upcoming catalysts
4
Cash runway
3.7 months
Cash & investments
$11M
Phase 3 programs
5

Verrica Pharmaceuticals Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 5, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.

Cash runway is approximately 3.7 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 6 concluded trials, 100% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 5, 2026 est. Next quarterly earnings (projected) Earnings —
May 15, 2027 Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3) Trial Milestone Phase 3
June 15, 2027 Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) Trial Milestone Phase 3
April 30, 2028 Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris) Trial Milestone Phase 3

Track VRCA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open VRCA in the tracker

Recent history

DateEventTypePhase
August 6, 2026 Quarterly results filed (8-K) Earnings —
June 9, 2026 8-K filed: Leadership change Corporate —
May 12, 2026 Quarterly results filed (8-K) Earnings —
March 11, 2026 Quarterly results filed (8-K) Earnings —
December 30, 2025 8-K filed: Leadership change Corporate —
November 24, 2025 8-K filed: Material agreement, Other event Corporate —
November 14, 2025 Quarterly results filed (8-K) Earnings —
August 12, 2025 Quarterly results filed (8-K) Earnings —
July 30, 2025 8-K filed: Listing / standard notice Corporate —
July 1, 2025 8-K filed: Material agreement, Reg FD disclosure Corporate —
June 12, 2025 8-K filed: Material agreement Corporate —
May 13, 2025 Quarterly results filed (8-K) Earnings —
April 25, 2025 8-K filed: Leadership change Corporate —
April 15, 2024 Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma Trial Milestone Phase 2
May 21, 2020 A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts Trial Milestone Phase 2
May 16, 2019 Cantharidin and Occlusion in Verruca Epithelium Trial Milestone Phase 2
November 26, 2018 Cantharidin Application in Molluscum Patients-1 Trial Milestone Phase 3
September 26, 2018 Cantharidin Application in Molluscum Patients Trial Milestone Phase 3
June 25, 2018 Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum. Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.